Exscientia PLC
NASDAQ:EXAI

Watchlist Manager
Exscientia PLC Logo
Exscientia PLC
NASDAQ:EXAI
Watchlist
Price: 4.84 USD Market Closed
Market Cap: 633.2m USD
Have any thoughts about
Exscientia PLC?
Write Note

Gross Margin
Exscientia PLC

-32.5%
Current
-26%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-32.5%
=
Gross Profit
-6.8m
/
Revenue
21m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
UK
Exscientia PLC
NASDAQ:EXAI
608.4m USD
-32%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
67%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
60%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
86%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
78%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
133.6B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
34.8B EUR
89%
Country UK
Market Cap 608.4m USD
Gross Margin
-32%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 312.7B USD
Gross Margin
67%
Country US
Market Cap 158.3B USD
Gross Margin
60%
Country US
Market Cap 116.2B USD
Gross Margin
86%
Country US
Market Cap 112.4B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 133.6B AUD
Gross Margin
52%
Country US
Market Cap 81.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.8B EUR
Gross Margin
89%
No Stocks Found

Exscientia PLC
Glance View

Market Cap
608.4m USD
Industry
Biotechnology

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The company is headquartered in Oxford, Oxfordshire and currently employs 208 full-time employees. The company went IPO on 2021-10-01. The firm's focus is on the discovery, design and development of small molecule drug candidates. The firm has built a complete end-to-end solution of artificial intelligence (AI), and experimental technologies for target identification, drug candidate design, translational models and patient selection. Its AI process is comprised of the four elements: Precision Target, Precision Design, Precision Experiment and Precision Medicine. Its AI-design includes a range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyze patient tissues to prioritize the molecules. The firm's lead drug candidate, EXS21546, is in early stage of development.

EXAI Intrinsic Value
4.74 USD
Overvaluation 2%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-32.5%
=
Gross Profit
-6.8m
/
Revenue
21m
What is the Gross Margin of Exscientia PLC?

Based on Exscientia PLC's most recent financial statements, the company has Gross Margin of -32.5%.